Autoimmune Hepatitis: Mycophenolate mofetil versus azathioprine as first line therapy

A recent open label, multicenter, randomized, controlled trial by Snijders et al.1 compared the efficacy and safety of mycophenolate mofetil (MMF) and azathioprine (AZA) as first-line induction therapy in treatment naive autoimmune hepatitis (AIH). The main findings were that MMF showed better tolerability and higher rate of biochemical response at 24 weeks. The study is a welcome addition to the limited number of randomized controlled trials in AIH. The authors present clear data but we think that several issues need further clarification.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research